1
|
Ambrosio N, Voci S, Gagliardi A, Palma E, Fresta M, Cosco D. Application of Biocompatible Drug Delivery Nanosystems for the Treatment of Naturally Occurring Cancer in Dogs. J Funct Biomater 2022; 13:jfb13030116. [PMID: 35997454 PMCID: PMC9397006 DOI: 10.3390/jfb13030116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2022] [Revised: 08/04/2022] [Accepted: 08/05/2022] [Indexed: 11/21/2022] Open
Abstract
Background: Cancer is a common disease in dogs, with a growing incidence related to the age of the animal. Nanotechnology is being employed in the veterinary field in the same manner as in human therapy. Aim: This review focuses on the application of biocompatible nanocarriers for the treatment of canine cancer, paying attention to the experimental studies performed on dogs with spontaneously occurring cancer. Methods: The most important experimental investigations based on the use of lipid and non-lipid nanosystems proposed for the treatment of canine cancer, such as liposomes and polymeric nanoparticles containing doxorubicin, paclitaxel and cisplatin, are described and their in vivo fate and antitumor features discussed. Conclusions: Dogs affected by spontaneous cancers are useful models for evaluating the efficacy of drug delivery systems containing antitumor compounds.
Collapse
|
2
|
Groer C, Zhang T, Lu R, Cai S, Mull D, Huang A, Forrest M, Berkland C, Aires D, Forrest ML. Intratumoral Cancer Chemotherapy with a Carrier-Based Immunogenic Cell-Death Eliciting Platinum (IV) Agent. Mol Pharm 2020; 17:4334-4345. [PMID: 32975949 DOI: 10.1021/acs.molpharmaceut.0c00781] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
A carrier-based, immunogenic cell death (ICD)-eliciting platinum(IV) chemotherapeutic agent was synthesized via complexation between an axially derivatized Pt(IV)-tocopherol and hyaluronan (HA)-tocopherol nanocarrier. The resultant HA-Pt(IV) complex demonstrated antiproliferative activity and induced calreticulin translocation, an indicator of ICD, in murine and human head and neck cancer (HNC) cells. The intratumorally administered HA-Pt(IV) treatments were tolerable and efficacious in both immunocompetent and immunodeficient mice with HNC, partially because of the direct cytotoxicity. Superior efficacy and survival were observed in the immunocompetent group, suggesting a possible Pt(IV)-induced immunological response, which would only manifest in animals with an intact immune system. Subsequent imaging of tumor tissues demonstrated increased macrophage infiltration in the HA-Pt(IV)-treated tumors compared to the nontreated controls and the cisplatin-treated tumors, suggesting favorable inflammatory activation. RNA sequencing of HA-Pt(IV)-treated tumors indicated that carbohydrate and vitamin metabolisms were the most important Kyoto Encyclopedia of Genes and Genomes pathways, and molecular function, biological process, and cellular component were highly enriched gene ontology categories.
Collapse
Affiliation(s)
- Chad Groer
- HylaPharm LLC, 2029 Becker Dr, Lawrence, Kansas 66047, United States
| | - Ti Zhang
- HylaPharm LLC, 2029 Becker Dr, Lawrence, Kansas 66047, United States
| | - Ruolin Lu
- Department of Pharmaceutical Chemistry, The University of Kansas, 2095 Constant Ave, Lawrence, Kansas 66047, United States
| | - Shuang Cai
- HylaPharm LLC, 2029 Becker Dr, Lawrence, Kansas 66047, United States
| | - Derek Mull
- HylaPharm LLC, 2029 Becker Dr, Lawrence, Kansas 66047, United States.,Department of Pharmaceutical Chemistry, The University of Kansas, 2095 Constant Ave, Lawrence, Kansas 66047, United States
| | - Aric Huang
- Department of Pharmaceutical Chemistry, The University of Kansas, 2095 Constant Ave, Lawrence, Kansas 66047, United States
| | - Melanie Forrest
- HylaPharm LLC, 2029 Becker Dr, Lawrence, Kansas 66047, United States
| | - Cory Berkland
- Department of Pharmaceutical Chemistry, The University of Kansas, 2095 Constant Ave, Lawrence, Kansas 66047, United States.,Department of Chemical and Petroleum Engineering, The University of Kansas, 1530 W 15th St, Lawrence, Kansas 66045, United States
| | - Daniel Aires
- HylaPharm LLC, 2029 Becker Dr, Lawrence, Kansas 66047, United States.,Division of Dermatology, Department of Internal Medicine, School of Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, Kansas 66160, United States
| | - Marcus Laird Forrest
- HylaPharm LLC, 2029 Becker Dr, Lawrence, Kansas 66047, United States.,Department of Pharmaceutical Chemistry, The University of Kansas, 2095 Constant Ave, Lawrence, Kansas 66047, United States
| |
Collapse
|